logo-loader
viewVolitionRx

VolitionRx eyeing launch in Europe of colorectal cancer test next year

The CE Mark will make the blood test potentially saleable in all 28 EU countries.

shutterstock_139099559.jpg
The VolitionRx test is based on blood sampling

Cancer diagnostics group VolitionRx Limited (NYSE:VNRX) continues to  make good progress and is looking to CE mark its colorectal blood test later this year ahead of a potential launch in Europe in early 2017.

The quarter to end September saw positive data on the test's ability to reduce the number of colonoscopies needed by 25%.

The CE Mark will make it potentially saleable in all 28 EU countries.

"......screening programs could reduce the number of unnecessary colonoscopies and relieve pressure on healthcare resources. Given the medical and market need, we believe that Volition is primed to offer its triage blood test to potentially thousands of FIT positive patients diagnosed in Europe each year," it said in a statement.

For the three months, Volition reported a net loss of $3.48 million compared to a loss of $2.96 million in the same period last year.

The firm had $12.5 million in cash as at September 30, compared to $14.5 million as of June 30, 2016 and $5.9 million as of December 31, 2015. 

Other highlights were the partnering with Hvidovre Hospital in Denmark for a new large world class 30,000 patient (and 90,000 sample) trial and the acquisition  of a  custom-designed research and development facility in Belgium which is expected to be fully operational by March next year.

Quick facts: VolitionRx

Price: 4.615 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $189.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx CEO discusses 'spectacular' results from Nu.Q proof of concept study

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds discusses with Proactive London's Andrew Scott the results from the latest proof of concept study on its Nu.Q cancer-test assay. He says the finding's have revealed an impressive ability to detect with accuracy non-Hodgkins lymphoma...

1 week, 1 day ago

2 min read